Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations.
Yolanda JerezIvan Márquez-RodasInmaculada AparicioManuel AlvaMiguel MartínSara López-TarruellaPublished in: Drugs (2020)
The poly-(ADP-ribose) polymerase (PARP) inhibitors olaparib and talazoparib, have recently been approved for use in patients with metastatic breast cancer (BC) and germline BRCA 1 or 2 mutations due to improved progression-free survival compared to chemotherapy. An increasing number of clinical trials are evaluating the role of PARP inhibitors (PARPi) in BC, alone and in combination with other therapies (including immunotherapy), as well as in earlier stages of the disease. This review describes the unique mechanism of action of these drugs and puts into clinical context the results of pivotal clinical trials. We also discuss the future development of PARPi in BC, their potential combination with other strategies, including chemotherapy and immune-checkpoint inhibitors, and the impact of these treatments in current genetic counselling.
Keyphrases
- clinical trial
- free survival
- metastatic breast cancer
- dna repair
- dna damage
- locally advanced
- phase ii
- breast cancer risk
- structural basis
- current status
- genome wide
- open label
- squamous cell carcinoma
- smoking cessation
- phase iii
- study protocol
- double blind
- oxidative stress
- risk assessment
- gene expression
- radiation therapy
- chemotherapy induced
- hiv testing
- drug induced